EGI
HRMY icon

EAM Global Investors’s Harmony Biosciences HRMY Stock Holding History

EAM Global Investors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-31,072
Closed -$1.51M – 203
2022
Q2 		$1.51M Sell
31,072
-7,040
-18% -$317K 0.37% 131
2022
Q1 		$1.85M Buy
+38,112
New +$1.55M 0.34% 154

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

EAM Global Investors's HRMY Position: Q3 2022 in Review

EAM Global Investors sold out of Harmony Biosciences (HRMY) in Q3 2022, closing a stake of 31,072 shares — an estimated $1.51M sold.

EAM Global Investors first reported a position in HRMY in Q1 2022 and held it in 2 quarters. The position peaked at $1.85M in Q1 2022. 203 funds tracked by Wall St. Rank hold HRMY as of Q3 2022.

  • EAM Global Investors reported no remaining Harmony Biosciences position as of Q3 2022 after selling out during the quarter.
  • EAM Global Investors sold 31,072 Harmony Biosciences shares in Q3 2022, an estimated $1.51M.
  • EAM Global Investors first reported a position in Harmony Biosciences in Q1 2022 and held it in 2 quarters.
  • EAM Global Investors's Harmony Biosciences position peaked at $1.85M in Q1 2022.
  • 203 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2022.

Based on EAM Global Investors's 13F filing for Q3 2022, filed 14 Nov 2022.